Skip to main content
Top
Published in: Inflammation 5/2021

01-10-2021 | Acute Respiratory Distress-Syndrome | Original Article

Anti-inflammatory Effects of Sweroside on LPS-Induced ALI in Mice Via Activating SIRT1

Authors: Juan Wang, Xiaolan Cai, Rui Ma, Dapeng Lei, Xinliang Pan, Fengshan Wang

Published in: Inflammation | Issue 5/2021

Login to get access

Abstract

Sweroside, as one of the main components of Swertia L. in Gentianaceae, has the effect of clearing heat and detoxifying. In previous studies, sweroside has been reported to have anti-inflammatory effect on LPS-induced inflammation by alleviating NF-κB signaling pathway. In this paper, we investigate the anti-inflammatory effects of sweroside by establishing LPS-induced acute lung injury (ALI) model in mice. Experimental results showed that sweroside could reduce the wet-to-dry ratio of the lung and inhibit MPO activity. In addition, it turned out that sweroside reduced pathological changes in lung tissue and the numbers of inflammatory cells. Moreover, sweroside significantly reduced the levels of inflammatory cytokines and down-regulated the NF-κB signaling pathway. And the results demonstrated that sweroside could increase the expression of SIRT1, and the protective effects of sweroside on LPS-induced ALI were reversed by SIRT1 inhibitor EX-527. In conclusion, sweroside can protect LPS-induced ALI mice through inhibiting inflammation.
Literature
1.
go back to reference Ferguson, N.D., F. Frutos-Vivar, A. Esteban, P. Fernandez-Segoviano, J.A. Aramburu, L. Najera, and T.E. Stewart. 2005. Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions. Crit Care Med 33: 2228–2234.CrossRef Ferguson, N.D., F. Frutos-Vivar, A. Esteban, P. Fernandez-Segoviano, J.A. Aramburu, L. Najera, and T.E. Stewart. 2005. Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions. Crit Care Med 33: 2228–2234.CrossRef
2.
go back to reference Goodman, R.B., J. Pugin, J.S. Lee, and M.A. Matthay. 2003. Cytokine-mediated inflammation in acute lung injury. Cytokine & Growth Factor Reviews 14: 523–535.CrossRef Goodman, R.B., J. Pugin, J.S. Lee, and M.A. Matthay. 2003. Cytokine-mediated inflammation in acute lung injury. Cytokine & Growth Factor Reviews 14: 523–535.CrossRef
3.
go back to reference Murray, J.F., M.A. Matthay, J.M. Luce, and M.R. Flick. 1988. An expanded definition of the adult respiratory-distress syndrome. American Review of Respiratory Disease 138: 720–723.CrossRef Murray, J.F., M.A. Matthay, J.M. Luce, and M.R. Flick. 1988. An expanded definition of the adult respiratory-distress syndrome. American Review of Respiratory Disease 138: 720–723.CrossRef
4.
go back to reference Ruffini, E., A. Parola, E. Papalia, P.L. Filosso, M. Mancuso, A. Oliaro, G. Actis-Dato, and G. Maggi. 2001. Frequency and mortality of acute lung injury and acute respiratory distress syndrome after pulmonary resection for bronchogenic carcinoma. European Journal of Cardio-Thoracic Surgery 20: 30–37.CrossRef Ruffini, E., A. Parola, E. Papalia, P.L. Filosso, M. Mancuso, A. Oliaro, G. Actis-Dato, and G. Maggi. 2001. Frequency and mortality of acute lung injury and acute respiratory distress syndrome after pulmonary resection for bronchogenic carcinoma. European Journal of Cardio-Thoracic Surgery 20: 30–37.CrossRef
5.
go back to reference Blank, R., and L.M. Napolitano. 2011. Epidemiology of ARDS and ALI. Crit Care Clin 27: 439–458.CrossRef Blank, R., and L.M. Napolitano. 2011. Epidemiology of ARDS and ALI. Crit Care Clin 27: 439–458.CrossRef
6.
go back to reference Fitzgerald, K.A., D.C. Rowe, and D.T. Golenbock. 2004. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect 6: 1361–1367.CrossRef Fitzgerald, K.A., D.C. Rowe, and D.T. Golenbock. 2004. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect 6: 1361–1367.CrossRef
7.
go back to reference Lu, Y.C., W.C. Yeh, and P.S. Ohashi. 2008. LPS/TLR4 signal transduction pathway. Cytokine 42: 145–151.CrossRef Lu, Y.C., W.C. Yeh, and P.S. Ohashi. 2008. LPS/TLR4 signal transduction pathway. Cytokine 42: 145–151.CrossRef
8.
go back to reference Wang, R., Z.Y. Dong, X.Z. Lan, Z.H. Liao, and M. Chen. 2019. Sweroside Alleviated LPS-induced inflammation via SIRT1 mediating NF-kappa B and FOXO1 signaling pathways in RAW264.7 Cells. Molecules 24. Wang, R., Z.Y. Dong, X.Z. Lan, Z.H. Liao, and M. Chen. 2019. Sweroside Alleviated LPS-induced inflammation via SIRT1 mediating NF-kappa B and FOXO1 signaling pathways in RAW264.7 Cells. Molecules 24.
9.
go back to reference Zhang, R., C.M. Wang, H.J. Jiang, X.G. Tian, W.J. Li, W. Liang, J.H. Yang, C.L. Zhong, Y.H. Chen, and T. Li. 2019. Protective effects of sweroside on IL-1-induced inflammation in rat articular chondrocytes through suppression of NF-B and mTORC1 signaling pathway. Inflammation 42: 496–505.CrossRef Zhang, R., C.M. Wang, H.J. Jiang, X.G. Tian, W.J. Li, W. Liang, J.H. Yang, C.L. Zhong, Y.H. Chen, and T. Li. 2019. Protective effects of sweroside on IL-1-induced inflammation in rat articular chondrocytes through suppression of NF-B and mTORC1 signaling pathway. Inflammation 42: 496–505.CrossRef
10.
go back to reference Yang, Q.L., F. Yang, J.T. Gong, X.W. Tang, G.Y. Wang, Z.T. Wang, and L. Yang. 2016. Sweroside ameliorates alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses. Acta Pharmacologica Sinica 37: 1218–1228.CrossRef Yang, Q.L., F. Yang, J.T. Gong, X.W. Tang, G.Y. Wang, Z.T. Wang, and L. Yang. 2016. Sweroside ameliorates alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice by regulating bile acids and suppressing pro-inflammatory responses. Acta Pharmacologica Sinica 37: 1218–1228.CrossRef
11.
go back to reference Spragg, R.G., G.R. Bernard, W. Checkley, J.R. Curtis, O. Gajic, G. Guyatt, J. Hall, E. Israel, M. Jain, D.M. Needham, A.G. Randolph, G.D. Rubenfeld, D. Schoenfeld, B.T. Thompson, L.B. Ware, D. Young, and A.L. Harabin. 2010. Beyond mortality future clinical research in acute lung injury. American Journal of Respiratory and Critical Care Medicine 181: 1121–1127.CrossRef Spragg, R.G., G.R. Bernard, W. Checkley, J.R. Curtis, O. Gajic, G. Guyatt, J. Hall, E. Israel, M. Jain, D.M. Needham, A.G. Randolph, G.D. Rubenfeld, D. Schoenfeld, B.T. Thompson, L.B. Ware, D. Young, and A.L. Harabin. 2010. Beyond mortality future clinical research in acute lung injury. American Journal of Respiratory and Critical Care Medicine 181: 1121–1127.CrossRef
12.
go back to reference Parker, J.C. 2011. Acute lung injury and pulmonary vascular permeability: use of transgenic models. Comprehensive Physiology 1: 835–882.CrossRef Parker, J.C. 2011. Acute lung injury and pulmonary vascular permeability: use of transgenic models. Comprehensive Physiology 1: 835–882.CrossRef
13.
go back to reference De Luca, D., M. Piastra, F. Tosi, S. Pulitano, A. Mancino, O. Genovese, D. Pietrini, and G. Conti. 2012. Pharmacological Therapies for pediatric and neonatal ALI/ARDS: an evidence-based review. Current Drug Targets 13: 906–916.CrossRef De Luca, D., M. Piastra, F. Tosi, S. Pulitano, A. Mancino, O. Genovese, D. Pietrini, and G. Conti. 2012. Pharmacological Therapies for pediatric and neonatal ALI/ARDS: an evidence-based review. Current Drug Targets 13: 906–916.CrossRef
14.
go back to reference Zhong, W.T., Y.W. Cui, Q.L. Yu, X.X. Xie, Y. Liu, M.M. Wei, X.X. Ci, and L.P. Peng. 2014. Modulation of LPS-Stimulated pulmonary inflammation by borneol in murine acute lung injury model. Inflammation 37: 1148–1157.CrossRef Zhong, W.T., Y.W. Cui, Q.L. Yu, X.X. Xie, Y. Liu, M.M. Wei, X.X. Ci, and L.P. Peng. 2014. Modulation of LPS-Stimulated pulmonary inflammation by borneol in murine acute lung injury model. Inflammation 37: 1148–1157.CrossRef
15.
go back to reference Chen, H., C. Bai, and X. Wang. 2010. The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine. Expert Rev Respir Med 4: 773–783.CrossRef Chen, H., C. Bai, and X. Wang. 2010. The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine. Expert Rev Respir Med 4: 773–783.CrossRef
16.
go back to reference Chignard, M., and V. Balloy. 2000. Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide. American Journal of Physiology-Lung Cellular and Molecular Physiology 279: L1083–L1090.CrossRef Chignard, M., and V. Balloy. 2000. Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide. American Journal of Physiology-Lung Cellular and Molecular Physiology 279: L1083–L1090.CrossRef
17.
go back to reference Kawai, T., and S. Akira. 2007. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13: 460–469.CrossRef Kawai, T., and S. Akira. 2007. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13: 460–469.CrossRef
18.
go back to reference Maruyama, K., Y. Takada, N. Ray, Y. Kishimoto, J.M. Penninger, H. Yasuda, and K. Matsuo. 2006. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. Journal of Immunology 177: 3799–3805.CrossRef Maruyama, K., Y. Takada, N. Ray, Y. Kishimoto, J.M. Penninger, H. Yasuda, and K. Matsuo. 2006. Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. Journal of Immunology 177: 3799–3805.CrossRef
19.
go back to reference Rahman, A., and F. Fazal. 2011. Blocking NF-kappaB: an inflammatory issue. Proc Am Thorac Soc 8: 497–503.CrossRef Rahman, A., and F. Fazal. 2011. Blocking NF-kappaB: an inflammatory issue. Proc Am Thorac Soc 8: 497–503.CrossRef
20.
go back to reference Xie, J., X.M. Zhang, and L. Zhang. 2013. Negative regulation of inflammation by SIRT1. Pharmacological Research 67: 60–67.CrossRef Xie, J., X.M. Zhang, and L. Zhang. 2013. Negative regulation of inflammation by SIRT1. Pharmacological Research 67: 60–67.CrossRef
21.
go back to reference Hwang, J.W., H.W. Yao, S. Caito, I.K. Sundar, and I. Rahman. 2013. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radical Biology and Medicine 61: 95–110.CrossRef Hwang, J.W., H.W. Yao, S. Caito, I.K. Sundar, and I. Rahman. 2013. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radical Biology and Medicine 61: 95–110.CrossRef
22.
go back to reference Yang, H.Y., W. Zhang, H. Pan, H.G. Feldser, E. Lainez, C. Miller, S. Leung, Z. Zhong, H.Z. Zhao, S. Sweitzer, et al. 2012. SIRT1 activators suppress inflammatory responses through promotion of p65 Deacetylation and inhibition of NF-kappa B activity. Plos One 7. Yang, H.Y., W. Zhang, H. Pan, H.G. Feldser, E. Lainez, C. Miller, S. Leung, Z. Zhong, H.Z. Zhao, S. Sweitzer, et al. 2012. SIRT1 activators suppress inflammatory responses through promotion of p65 Deacetylation and inhibition of NF-kappa B activity. Plos One 7.
23.
go back to reference Tian, Y.L., J.T. Ma, W.D. Wang, L.J. Zhang, J. Xu, K. Wang, and D.F. Li. 2016. Resveratrol supplement inhibited the NF-kappa B inflammation pathway through activating AMPK alpha-SIRT1 pathway in mice with fatty liver. Molecular and Cellular Biochemistry 422: 75–84.CrossRef Tian, Y.L., J.T. Ma, W.D. Wang, L.J. Zhang, J. Xu, K. Wang, and D.F. Li. 2016. Resveratrol supplement inhibited the NF-kappa B inflammation pathway through activating AMPK alpha-SIRT1 pathway in mice with fatty liver. Molecular and Cellular Biochemistry 422: 75–84.CrossRef
24.
go back to reference Yuan, Q., D.Q. Zhang, C.Q. Liu, C.C. Zhang, and D. Yuan. 2018. Chikusetsusaponin V inhibits LPS-activated inflammatory responses via SIRT1/NF-B signaling pathway in RAW264.7 cells. Inflammation 41: 2149–2159.CrossRef Yuan, Q., D.Q. Zhang, C.Q. Liu, C.C. Zhang, and D. Yuan. 2018. Chikusetsusaponin V inhibits LPS-activated inflammatory responses via SIRT1/NF-B signaling pathway in RAW264.7 cells. Inflammation 41: 2149–2159.CrossRef
Metadata
Title
Anti-inflammatory Effects of Sweroside on LPS-Induced ALI in Mice Via Activating SIRT1
Authors
Juan Wang
Xiaolan Cai
Rui Ma
Dapeng Lei
Xinliang Pan
Fengshan Wang
Publication date
01-10-2021
Publisher
Springer US
Published in
Inflammation / Issue 5/2021
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-021-01473-4

Other articles of this Issue 5/2021

Inflammation 5/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine